Inari Medical
9272 Jeronimo Rd. Suite 124
Irvine
California
92618
United States
Tel: 949-600-8433
Website: http://inarimedical.com/
107 articles about Inari Medical
-
Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry
11/13/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism (“PE”) patients. The results were strongly posit
-
Inari Medical Reports Third Quarter 2020 Financial Results
11/12/2020
Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its third quarter ended September 30, 2020.
-
Inari Medical Appoints Kevin Strange as VP of Strategy and Business Development and Angela Ahmad as General Counsel
11/12/2020
Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced the appointment of Kevin Strange as VP of Strategy and Business Development, and Angela Ahmad as General Counsel.
-
Inari Medical to Participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum
11/6/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) announced today that its management team will participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020. About Inari Medical, Inc. Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, n
-
Inari Medical to Announce Third Quarter 2020 Financial Results
10/29/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the third quarter of 2020 after market close on Thursday, November 12, 2020.
-
Inari Medical Announces Presentation of Positive Results from First Patients in Real World FLASH Registry
10/19/2020
- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive results of the first 230 patients enrolled in its FLASH study. Interim data of this real world pulmonary embolism (“PE”) population, including high- and intermediate-risk patients, was obtained across 19 US sites. Results were
-
Inari Medical Prospective Clinical Data on the FlowTriever System to be Presented in Late-Breaking Session at TCT Connect
9/21/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the interim results from the FLASH study have been accepted for presentation in a late-breaking clinical science session at TCT Connect. The FLASH study is evaluating the safety and effectiveness of the FlowTriever
-
Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer
9/17/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the promotion of Drew Hykes to Chief Operating Officer, effective September 1, 2020
-
Inari Medical to Participate in Upcoming Investor Conferences
8/27/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the management team is scheduled to speak at the following upcoming investor conferences.
-
Inari Medical Reports Second Quarter 2020 Financial Results
8/11/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its second quarter ended June 30, 2020.
-
Inari Medical to Present at the Canaccord Genuity 40th Annual Growth Conference
7/29/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced the company will be participating in the upcoming Canaccord Genuity 40th Annual Virtual Growth Conference.
-
Inari Medical to Announce Second Quarter 2020 Financial Results
7/28/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced it will release financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020.
-
Inari Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
5/27/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the closing of its initial public offering of 9,432,949 shares of its common stock, including the exercise in full of the underwriters’ option to purchase 1,230,384 additional shares of common stock, at the initial public offering price of $19.00 per share
-
Inari Medical Announces Pricing of Its Upsized Initial Public Offering
5/21/2020
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the pricing of its upsized initial public offering of 8,202,565 shares of its common stock at a public offering price of $19.00 per share, f
-
Inari Medical Launches Initial Public Offering - May 18, 2020
5/18/2020
Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced that it has launched the roadshow for its initial public offering of shares of its common stock.
-
Inari Medical Appoints Cynthia Lucchese and Catherine Szyman to the Company's Board of Directors
1/28/2020
Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Cynthia Lucchese and Catherine Szyman to the company's Board of Directors.
-
Prospective Clinical Data on the ClotTriever System Shows Excellent Results in the Treatment of Deep Vein Thrombosis
11/6/2019
Inari Medical, Inc. announced the presentation of early outcomes from the ClotTriever Outcomes Registry using the ClotTriever Mechanical Thrombectomy System for treatment of acute and chronic lower extremity deep vein thrombosis Initial results for the first 50 patients were presented by principal investigator David J. Dexter, MD, a vascular surgeon at Sentara Healthcare in Norfolk, VA at the VIVA 2019 late-breaking clinical trials session held in Las Vegas, NV.
-
Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer
7/2/2019
Dr. Tu is a pioneer in definitive catheter-based treatment of pulmonary embolism
-
Inari Medical Announces Publication of FLARE IDE Study Results
5/7/2019
Inari Medical, Inc. announced the publication of its 106-patient prospective multicenter FlowTriever Mechanical Pulmonary Embolectomy study for the treatment of intermediate-risk pulmonary embolism.
-
Cold Spring Harbor Laboratory announces exclusive license with plant breeding start-up Inari
4/16/2019
Cold Spring Harbor Laboratory announced an exclusive licensing agreement with partner Inari, a company that is advancing plant breeding by tapping nature's genetic diversity.